Risk of isolated nodal failure for non-small cell lung cancer (NSCLC) treated with the elective nodal irradiation (ENI) using 3D-conformal radiotherapy (3D-CRT) techniques – A retrospective analysis

References

• Belderbos JSA, Heemsbergen WD, De Jaeger K, Baas P, Lebesque JV. Final results of a phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2006; 66: 126–34
   PubMed Web of Science ®Google Scholar
• Bradley J, Graham MV, Winter K, Purdy JA, Komaki R, Roa WH, et al. Toxicity and outcome results of RTOG 9311: A phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2005; 61: 318–28
   PubMed Web of Science ®Google Scholar
• Chen M, Hayman JA, Ten Haken RK, Tatro D, Fernando S, Kong FM. Long-term results of high-dose conformal radiotherapy for patients with medically inoperable T1-3N0 non-small-cell lung cancer: Is low incidence of regional failure due to incidental nodal irradiation?. Int J Radiat Oncol Biol Phys 2006; 64: 120–6
   PubMed Web of Science ®Google Scholar
• Cheung PCF, Mackillop WJ, Dixon P, Brundage MD, Youssef YM, Zhou S. Involved-field radiotherapy alone for early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2000; 48: 703–10
   PubMedGoogle Scholar
• McGarry RC, Papiez L, Williams M, Whitford T, Timmerman RD. Stereotactic body radiation therapy of early-stage non-small cell lung carcinoma: Phase I study. Int J Radiat Oncol Biol Phys 2005; 63: 1010–5
   PubMed Web of Science ®Google Scholar
• Rosenzweig KE, Sim SE, Mychalczak B, Braban LE, Schindelheim R, Leibel SA. Elective nodal irradiation in the treatment of non-small cell lung cancer with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 2001; 50: 681–5
   PubMed Web of Science ®Google Scholar
• Zimmermann FB, Geinitz H, Schill S, Thamm R, Nieder C, Schratzenstaller U, et al. Stereotactic hypofractionated radiotherapy for stage I (T1-2 N0 M0) non-small-cell lung cancer. Acta Oncol 2006; 45: 796–801
   PubMed Web of Science ®Google Scholar
• Ginsberg RJ, Rubinstein L, for the Lung Cancer Study Group. A randomised study of lobectomy versus limited resection for patients with T1N0 non-small-cell lung cancer. Ann Thorac Surg 1995;60:615–22.
   PubMed Web of Science ®Google Scholar
• Kotoulas CS, Foroulis CN, Kostikas K, Konstantinou M, Kalkandi P, Dimadi M, et al. Involvement of lymphatic metastatic spread in non-small cell lung cancer accordingly to the primary cancer location. Lung Cancer 2004; 44: 183–91
   PubMed Web of Science ®Google Scholar
• Rosenzweig KE, Fox JL, Yorke E, Amols H, Jackson A, Rusch V, et al. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung carcinoma. Cancer 2005; 103: 2118–27
   PubMed Web of Science ®Google Scholar
• Senan S, Burgers S, Samson MJ, van Klavreren RJ, Oei SS, van Sornsen de Koste J, et al. Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapy. Int J Radiat Oncol Biol Phys 2002; 54: 999–1006
   PubMed Web of Science ®Google Scholar
• Jeremic B. Incidental irradiation of nodal regions at risk during limited-field radiotherapy (RT) in dose-escalation studies in non-small cell lung cancer (NSCLC): Enough to convert no-elective into elective nodal irradiation (ENI)?. Radiother Oncol 2003; 71: 123–5
   Google Scholar
• Chapet O, Kong F-M, Quint LE, Chang AC, Ten Haken RK, Eisbruch A, et al. CT-based definition of thoracic lymph node stations: an atlas from the University of Michigan. Int J Radiat Oncol Biol Phys 2005; 63: 170–8
   PubMed Web of Science ®Google Scholar
• Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest 1997; 111: 1718–23
   PubMed Web of Science ®Google Scholar
• Thomas CR, Giroux DJ, Stelzer KJ, Craig JB, Laufman LR, Taylor SA, et al. Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: A phase II study of the Southwest Oncology Group (SWOG-9229). Int J Radiat Oncol Biol Phys 1998; 40: 1039–47
   Google Scholar
• Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organisation for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341–6
   PubMed Web of Science ®Google Scholar
• Sibley GS, Jamieson TA, Marks LB, Anscher MS, Prosnitz LR. Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: The Duke experience. Int J Radiat Oncol Biol 1998; 40: 149–54
   PubMed Web of Science ®Google Scholar
• Slotman BJ, Antonisse IE, Njo KH. Limited field irradiation in early stage (T1-2N0) non-small cell lung cancer. Radiother Oncol 1996; 41: 41–4
   PubMed Web of Science ®Google Scholar
• Emami B, Mirkovic N, Scott C, Craig JB, Laufman LR, Taylor SA, et al. The impact of regional nodal radiotherapy (dose/volume) on regional progression and survival in unresectable non-small cell lung cancer: An analysis of RTOG data. Lung Cancer 2003; 41: 207–14
   PubMed Web of Science ®Google Scholar
• Kepka L, Fijuth J, Zawadzka A, Blatkiewicz D, Zajda K, Wierzchowski M. Accelerated Radiotherapy (aRT) for locally advanced NSCLC: Significance of bulky disease?. Radiother Oncol 2002; 64: S254
   Google Scholar
• Kelsey CR, Light KL, Marks LB. Patterns of failure after resection of non-small-cell Lung Cancer: Implications for postoperative radiation therapy volume. Int J Radiat Oncol Biol Phys 2006; 65: 1097–105
   PubMed Web of Science ®Google Scholar
• Giraud P, De Rycke Y, Lavole A, Milleron B, Cosset J-M, Rosenzweig KE. Probability of mediastinal involvement in non-small-cell lung cancer: A statistical definition of the clinical target volume for 3-dimensional conformal radiotherapy?. Int J Radiat Oncol Biol Phys 2006; 64: 127–35
   PubMed Web of Science ®Google Scholar
• Sawyer TE, Bonner JA, Gould PM, Garces YI, Foote RL, Lange CM, et al. Predictors of subclinical nodal involvement in clinical stages I and II non-small cell lung cancer. Implications in the inoperable and three dimensional dose-escalation settings. Int J Radiat Oncol Biol Phys 1999; 43: 965–70
   Google Scholar
• Nohl-Oser HC. An investigation of the anatomy of the lymphatic drainage of the lungs as shown by the lymphatic spread of bronchial carcinoma. Ann R Coll Surg Engl 1972; 51: 157–76
   Google Scholar
• Williams TE, Thomas CR, Turrisi AT. Counterpoint: Better radiation treatment of NSCLC using new techniques without elective nodal irradiation. Semin Radiat Oncol 2000; 10: 315–23
   PubMed Web of Science ®Google Scholar
• Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Bogaert J, Maes A, et al. Lymph-node staging in non-small cell lung cancer with FDG-PET scan: A prospective study on 690 lymph node stations from 68 patients. J Clin Oncol 1998; 16: 2142–9
   PubMed Web of Science ®Google Scholar